0239 (0239) Fair Value & Analysis

Healthcare · Market cap HK$742M

0 0239 0239 · HK

PriceHK$2.38

Fair ValueHK$6.07

Upside+155.0%

Quality72/100

Evidence: High Range HK$4.50 – HK$7.52

Fair value as of: Jul 1, 2026

From 25 valuation models · updated today

Share price −2.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.31 – HK$2.53 · fair‑value band HK$4.50 – HK$7.52 · the HK$2.38 price screens below the HK$6.07 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0239 (0239) currently trades at HK$2.38, while our model-based Fair Value estimate is HK$6.07 — implying the stock looks roughly 155.0% undervalued today. We read business quality at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0239 generated revenue of HK$214M at a net margin of 42.6%. Revenue grew 14.1% year over year. It earns a return on equity of 12.6%. The balance sheet holds a net cash position of HK$324M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$214M

Revenue growth (YoY) +14.1%

Net margin 42.6%

Return on equity 12.6%

Free cash flow HK$112M FY2025

P/E ratio 8.2

More key figures

Operating margin 51.2%

EPS (TTM) HK$0.1300

Dividend yield 2.8%

EPS growth (YoY) +65.3%

Net cash HK$324M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0239 reported revenue of HK$214M in FY2025 versus HK$140M in FY2021, a compound +11.2%/yr. Reported net income was HK$91.3M in FY2025, compounding +24.4%/yr from FY2021.

Revenue +11.2%/yr

FY21 HK$140M

FY22 HK$147M

FY23 HK$259M

FY24 HK$237M

FY25 HK$214M

Net income +24.4%/yr

FY21 HK$38.2M

FY22 HK$30.0M

FY23 HK$105M

FY24 HK$78.6M

FY25 HK$91.3M

Is 0239 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0239 (0239) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$6.07 versus a price of HK$2.38 — about +155% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0239?

Our model-based fair value for 0239 is HK$6.07 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$2.38.

What is the quality score of 0239?

0239 has a Quality Score of 72/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0239 (0239)?

0239 reported trailing-twelve-month revenue of about HK$214M (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0239?

The net profit margin of 0239 is about 42.6%, meaning it keeps roughly 42.6% of revenue as net income. Based on the latest reported figures.

Does 0239 pay a dividend?

0239 currently shows a dividend yield of about 2.83% relative to its recent price (as of Jul 1, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.